Comfortable leader
42 companies value 131 bn revenue 14 bn margin -20.6% free cash flow -1.1 bn avg. score 0.9
NTRA holds 44.0% of the group's value, 2.7x the runner-up
| Rank | Ticker | Company | Share | Value | Revenue | Margin | FCF | 5 years | FCF/px | Yield | What it does · why it is here |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NTRA | Natera United States · score 2.6 | 44% | 58 bn | 2.7 bn | -7.1% | 0.1 bn | 0.1% | — | Genetic testing for prenatal care, cancer and transplants · Leader in DNA testing for pregnancy, oncology and transplants | |
| 2 | GH | Guardant Health United States · score 0.0 | 16% | 21 bn | 1.2 bn | -38.3% | -0.2 bn | -1.1% | — | Blood tests for precision oncology · Liquid biopsy for oncology: detects cancer with a blood test | |
| 3 | TEM | Tempus AI, Inc. United States · score 0.0 | 9% | 12 bn | 1.4 bn | -17.8% | -0.3 bn | -2.3% | — | Intelligent testing linking lab results to clinical data · Illinois — revenue of $1.4bn | |
| 4 | CAI | Caris Life Sciences, Inc. United States · score 4.9 | 7% | 8.7 bn | 1.0 bn | 10.6% | 0.1 bn | 1.7% | — | AI-driven drug discovery and precision medicine · Texas — revenue of $990m | |
| 5 | GRAL | GRAIL, Inc. United States · score 0.0 | 4% | 5.5 bn | 0.2 bn | -236.9% | -0.3 bn | -5.4% | — | Early cancer detection at population scale · California — revenue of $165m | |
| 6 | BLLN | BillionToOne, Inc. United States · score 4.7 | 4% | 4.8 bn | 0.4 bn | 9.5% | 0.0 bn | 0.7% | — | Non-invasive liquid biopsy with sequencing and AI · California — revenue of $397m | |
| 7 | ADPT | Adaptive Biotechnologies Corp United States · score 0.3 | 3% | 3.8 bn | 0.3 bn | -20.7% | -0.0 bn | -0.6% | — | Immune system sequencing for diagnostics and research · Washington — revenue of $308m | |
| 8 | VCYT | VERACYTE, INC. United States · score 5.7 | 3% | 3.5 bn | 0.6 bn | 20.4% | 0.2 bn | 4.7% | — | Genomic tests for cancer diagnosis · California — revenue of $562m | |
| 9 | CDNA | CareDx, Inc. United States · score 5.2 | 3% | 3.5 bn | 0.5 bn | 24.2% | 0.1 bn | 2.7% | — | Precision medicine for transplant patients · California — revenue of $458m | |
| 10 | NEO | NEOGENOMICS INC United States · score 0.4 | 2% | 2.1 bn | 0.8 bn | -6.8% | -0.0 bn | -0.3% | — | Network of cancer testing labs in the US and the UK · Florida — revenue of $766m | |
| 11 | WGS | GeneDx Holdings Corp. United States · score 0.0 | 2% | 2.0 bn | 0.5 bn | -23.4% | -0.1 bn | -3.8% | — | Exome and genome testing for clinical diagnosis · Connecticut — revenue of $454m | |
| 12 | PSNL | Personalis, Inc. United States · score 0.0 | 1% | 1.7 bn | 0.1 bn | -153.8% | -0.1 bn | -6.0% | — | Advanced cancer genomic testing · California — revenue of $70m | |
| 13 | CSTL | CASTLE BIOSCIENCES INC United States · score 1.0 | 1% | 1.0 bn | 0.4 bn | -5.4% | 0.0 bn | 0.0% | — | Molecular diagnostics for skin cancers and other diseases · Texas — revenue of $357m | |
| 14 | QDEL | QuidelOrtho Corp United States · score 0.0 | 1% | 0.9 bn | 2.7 bn | -39.2% | -0.2 bn | -24.1% | — | Diagnostics with factories in the US, UK and China · California — revenue of $2.7bn | |
| 15 | FLGT | Fulgent Genetics, Inc. United States · score 0.3 | 0% | 0.6 bn | 0.3 bn | -26.0% | -0.1 bn | -18.8% | — | Lab services and therapeutic development · California — revenue of $324m | |
| 16 | NNNN | Anbio Biotechnology Germany · score 3.0 | 0% | 0.5 bn | 0.0 bn | 74.0% | -0.0 bn | -1.4% | — | Rapid diagnostic tests, with operations in Europe · Germany — revenue of $9m | |
| 17 | MYGN | MYRIAD GENETICS INC United States · score 2.2 | 0% | 0.4 bn | 0.8 bn | -14.0% | 0.0 bn | 1.9% | — | Molecular and genetic tests for patients and doctors · Utah — revenue of $807m | |
| 18 | YDES | YD Bio Ltd Taiwan · score 2.0 | 0% | 0.4 bn | 0.0 bn | 24.7% | -0.0 bn | -2.0% | — | Diagnostics and health products · Taiwan — revenue of $1m | |
| 19 | OSUR | ORASURE TECHNOLOGIES INC United States · score 0.0 | 0% | 0.3 bn | 0.1 bn | -43.7% | -0.1 bn | -18.9% | — | Rapid HIV, hepatitis C and covid tests, including at-home tests · Pennsylvania — revenue of $112m | |
| 20 | BDSX | BIODESIX INC United States · score 0.0 | 0% | 0.2 bn | 0.1 bn | -27.0% | -0.0 bn | -8.2% | — | Diagnostics, with a focus on lung solutions · Colorado — revenue of $103m | |
| 21 | XGN | EXAGEN INC. United States · score 0.0 | 0% | 0.2 bn | 0.1 bn | -26.6% | -0.0 bn | -4.2% | — | AVISE tests for diagnosing rheumatic and autoimmune diseases · California — revenue of $71m | |
| 22 | BNR | Burning Rock Biotech Ltd China · score 0.4 | 0% | 0.1 bn | 0.1 bn | -10.3% | 0.0 bn | -3.6% | — | Genomic cancer diagnostics in China · China — revenue of $77m | |
| 23 | LUCD | Lucid Diagnostics Inc. United States · score 0.0 | 0% | 0.1 bn | 0.0 bn | -959.8% | -0.1 bn | -61.6% | — | Tests for early detection of esophageal cancer · New York — revenue of $5m | |
| 24 | IMDX | Insight Molecular Diagnostics Inc. United States · score 0.0 | 0% | 0.1 bn | 0.0 bn | -30x | -0.0 bn | -32.8% | — | Molecular diagnostic kits for use in the lab itself · Tennessee — revenue of $2m | |
| 25 | SERA | SERA PROGNOSTICS, INC. United States · score 0.0 | 0% | 0.1 bn | 0.0 bn | -475x | -0.0 bn | -35.1% | — | Proteomic tests for maternal and neonatal health · Utah | |
| 26 | MDXH | MDxHealth SA Belgium · score 0.0 | 0% | 0.0 bn | 0.1 bn | -31.1% | 0.0 bn | -19.1% | — | Molecular prostate cancer tests (Confirm mdx, GPS mdx, Exo mdx) for urologists in the US · Belgium — revenue of $108m | |
| 27 | TRIB | TRINITY BIOTECH PLC Ireland · score 0.0 | 0% | 0.0 bn | 0.0 bn | -82.0% | -0.0 bn | -89.8% | — | Human diagnostics and biosensors for diabetes, from Ireland · Ireland — revenue of $44m | |
| 28 | PRPO | Precipio, Inc. United States · score 2.6 | 0% | 0.0 bn | 0.0 bn | -4.5% | 0.0 bn | 2.0% | — | Diagnostic biotech for blood cancers · Connecticut — revenue of $27m | |
| 29 | BIAF | bioAffinity Technologies, Inc. United States · score 0.0 | 0% | 0.0 bn | 0.0 bn | -257.3% | -0.0 bn | -256.9% | — | Noninvasive AI-powered lung cancer diagnostics · Texas — revenue of $6m | |
| 30 | CNSY | CERENOME, INC. United States · score 0.0 | 0% | 0.0 bn | 0.0 bn | -620.7% | -0.0 bn | -188.4% | — | Cerebrospinal fluid tests for central nervous system cancers and a radiopharmaceutical in development · Texas — revenue of $4m | |
| 31 | BMRA | BIOMERICA INC United States · score 0.0 | 0% | 0.0 bn | 0.0 bn | -115.5% | 0.0 bn | -48.8% | — | Patented diagnostic and therapeutic products · California — revenue of $4m | |
| 32 | ACON | Aclarion, Inc. United States · score 0.0 | 0% | 0.0 bn | 0.0 bn | -109x | -0.0 bn | -150.2% | — | Magnetic resonance spectroscopy technology · Colorado | |
| 33 | VNRX | VOLITIONRX LTD United States · score 0.0 | 0% | 0.0 bn | 0.0 bn | — | -0.0 bn | -384.0% | — | Epigenetic blood tests for human and veterinary cancer · Nevada — revenue of $2m | |
| 34 | CDIO | Cardio Diagnostics Holdings, Inc. United States · score 0.0 | 0% | 0.0 bn | 0.0 bn | -462x | -0.0 bn | -118.9% | — | Epigenetics-based clinical tests for cardiovascular disease · Illinois | |
| 35 | INBS | INTELLIGENT BIO SOLUTIONS INC. United States · score 0.0 | 0% | 0.0 bn | 0.0 bn | -294.9% | -0.0 bn | -262.0% | — | Medical technology for rapid, noninvasive testing · New York — revenue of $4m | |
| 36 | AIDX | 20/20 Biolabs, Inc. United States · score 0.0 | 0% | 0.0 bn | 0.0 bn | -285.0% | 0.0 bn | -84.6% | — | AI blood tests for early cancer detection · Maryland — revenue of $2m | |
| 37 | VRAX | Virax Biolabs Group Ltd United Kingdom · score 0.0 | 0% | 0.0 bn | 0.0 bn | -419x | 0.0 bn | -256.7% | — | Infectious disease and immunology diagnostics · United Kingdom | |
| 38 | BJDX | Bluejay Diagnostics, Inc. United States · score 0.0 | 0% | 0.0 bn | — | — | -0.0 bn | -196.0% | — | Critical care diagnostics with a focus on sepsis · Massachusetts | |
| 39 | NIKI | Niki BioSolutions, Inc. United Kingdom · score 0.0 | 0% | 0.0 bn | — | — | 0.0 bn | -108.1% | — | MicroRNA blood tests for Alzheimer's, successor to a clinical-stage biopharmaceutical company · United Kingdom | |
| 40 | ONCO | Onconetix, Inc. United States · score 0.5 | — | — | 0.0 bn | -16x | -0.0 bn | — | — | Proclarix blood test for prostate cancer diagnosis · Ohio | |
| 41 | AIMD | Ainos, Inc. United States · score 0.1 | — | — | 0.0 bn | -1033x | 0.0 bn | — | — | Artificial olfaction technology and immunotherapy, from 1984 · Texas | |
| 42 | FRNM | Freenome, Inc. United States · score 0.9 | — | — | — | — | 0.0 bn | — | — | — | Blood tests for early cancer detection · California |
Other industries in the same sector
- Sector overview
- Large-cap pharmaceuticals 9 companies
- Biotechnology 57 companies
- European pharmaceuticals 5 companies
- Lab tools and consumables 37 companies
- Health insurance and services 17 companies
- Medical devices 87 companies
- Specialty pharmaceuticals 77 companies
- Pharmaceutical distribution 7 companies
- Clinical-stage pharmaceuticals 251 companies
- Robotic surgery and advanced medtech 9 companies
- Hospitals 23 companies
- Emerging biotech 5 companies
and 22 industries more
- Vaccines and mRNA 14 companies
- Clinical-stage biotech 200 companies
- Generics and biosimilars 10 companies
- Animal health 7 companies
- Contract research (CRO) 10 companies
- Consumer health (OTC) 4 companies
- Healthcare software 18 companies
- Rehabilitation and home care 15 companies
- Genomics and sequencing 9 companies
- Structural heart 8 companies
- Ophthalmology 12 companies
- Medical imaging and hospital equipment 16 companies
- Diagnostic labs 6 companies
- Medical and dental supply distribution 3 companies
- Diabetes monitoring 9 companies
- Pharmaceutical royalties 5 companies
- Respiratory and sleep therapy 9 companies
- Orthopedic implants 17 companies
- Dialysis 3 companies
- Telehealth and digital health 12 companies
- Dental 4 companies
- Medical and recreational cannabis 16 companies
What this is. A catalogue, not a guide. Every industry with stocks listed on the NYSE or NASDAQ, the companies contending for its leadership, what each one does according to its own annual report, and the balance sheet it filed with the SEC.
The score runs from 0 to 10 and compares each company with every other one in the almanac on cash generation, profitability, debt, dividends and consistency over the last five years. The higher it is, the better the company fares in that comparison. Curious how much each part weighs? Ask at the bottom of the page.
The score runs from 0 to 10 and compares each company with every other one in the almanac on cash generation, profitability, debt, dividends and consistency over the last five years. The higher it is, the better the company fares in that comparison. Curious how much each part weighs? Ask at the bottom of the page.